The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
To be eligible for this study, patients must have a confirmed diagnosis of AL amyloidosis without significant cardiac (New York Heart Association class IV) disease and not be on kidney dialysis. Additionally, after testing, their blood must not contain antibodies to mouse proteins. The study requires an intravenous infusion, over 10 minutes, of the radiolabeled antibody, followed 48 hours later by a PET/CT scan. A repeat scan is done 5 or 7 days after infusion of the antibody. A 5 ml blood specimen needs to be furnished 4 and 8 weeks after the antibody infusion.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
38
Single infusion of radiolabeled antibody: 2mCi (1 mg)
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Radioimmunoimaging of AL amyloid deposits
Time frame: 36 months
Imaging of amyloid deposits as determined by PET/CT
Time frame: 10-14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.